Background: Doravirine is a novel HIV-1 NNRTI recently shown to be non-inferior to both darunavir/ritonavir and efavirenz in combination therapy with two NRTIs in treatment-naive patients. Doravirine has an in vitro resistance profile that is distinct from other NNRTIs and retains activity against viruses containing the most frequently transmitted NNRTI mutations.
Introduction
Intensive scale-up of antiretrovirals worldwide has led to a dramatic decrease in HIV-1-related morbidity and mortality. Despite this success, the expansion of treatment has been accompanied by a significant increase in the prevalence of acquired and transmitted HIV drug resistance, mostly driven by NNRTIs. 1 Doravirine is a novel HIV-1 NNRTI in Phase III clinical development with an in vitro resistance profile that is distinct from other NNRTIs, retaining activity against viruses containing the most frequently transmitted NNRTI mutations, such as K103N, E138K, Y181C and G190A. 2 Doravirine selects for distinct mutations in vitro, including mutations at positions 106, 108, 227 and 234 with multiple mutations required for significant levels of resistance. 3 Only a few single mutations were associated with a .10-fold reduced susceptibility to doravirine, including V106A, Y188L and M230L. 4 Furthermore, the double and triple mutants V106A/F227L, V106/L234I, V106A/F227L/L234I or V106A/G190A/F227L all showed substantial resistance to doravirine. [3] [4] [5] Recent Phase III trials showed that doravirine has non-inferior efficacy when compared with darunavir/ritonavir (800/100 mg) or efavirenz in combination with two NRTIs in treatment-naive patients. 6, 7 Data on the occurrence of doravirine resistanceassociated mutations in treatment-naive patients are crucial to inform the further provision of treatment.
The aim of this study was to examine the prevalence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients in Europe over time across various subtypes and to compare this prevalence with those known for currently available NNRTIs.
Methods
All bulk HIV resistance genotypes performed for routine clinical purposes for drug-naive HIV patients care performed between 2010 and 2016 were retrieved at six reference laboratories: two in France (Pitié-Salpêtrière and Bichat Claude Bernard hospitals; n " 2941), three in Italy (University of Rome 'Tor Vergata', INMI Spallanzani-IRCCS, Modena Hospital; n " 4063) and one in Greece (Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens; n " 1230). In addition, sequence data from drug-naive patients were provided by a number of centres included in the ARCA database (www.dbarca. net; n " 1530) in Italy. Doravirine resistance-associated mutations identified in vitro and used to define doravirine resistance in this study were: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C.
2-5 HIV-1 with at least one of these mutations was considered as resistant to doravirine.
NRTI (zidovudine, emtricitabine/lamivudine, abacavir, tenofovir) and NNRTI (efavirenz, rilpivirine, nevirapine and etravirine) mutations associated with resistance were those listed in the ANRS algorithm (table of rules 2017; www.hivfrenchresistance.org), in the IAS list 2017 (www.iasusa.org) and in the Stanford HIV drug resistance database (HIVdbversion 8.5; https://hivdb. stanford.edu/dr-summary/resistance-notes/NNRTI/).
Resistance interpretation was made using the SmartGene Integrated Database Network System (SmartGene, Switzerland; http://www.smart gene.com) according to the Stanford algorithm (https://hivdb.stanford.edu) or the ANRS algorithm (http://www.hivfrenchresistance.org).
HIV-1 subtype was determined based on the RT and protease coding regions by the SmartGene algorithm (SmartGene, Switzerland) or by phylogenetic analyses, using reference sequences of HIV-1 subtypes and circulating recombinant forms (CRFs) from the Los Alamos Database (https:// www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). Between-group comparisons were carried out with Fisher's exact test using the BiostatTGV web site (https://biostatgv.sentiweb.fr/? module"tests).
Results

Distribution of HIV-1 subtypes in antiretroviral-naive patients
A total a 9764 RT sequences obtained between 2010 and 2016 for HIV-1 treatment-naive patients in routine clinical care were analysed (2010-12, n " 4939; 2013-16, n " 4825). The distribution of subtypes was 53.0% B and 47.0% non-B subtypes. Subtypes with a prevalence .3.0% included CRF02_AG (14.6%), A (6.3%), C (3.3%) and F (3.2%). There was a significant increase in non-B subtypes in 2013-16 with respect to 2010-12 (49.4% versus 42.7%, respectively, P , 0.001).
Prevalence of doravirine resistance-associated mutations
The overall prevalence of sequences with at least one doravirine resistance-associated mutation was 1.4% (n " 137). The number of sequences with one, two, three and four doravirine resistanceassociated mutations was 127 (1.3%), 8 (0.1%), 1 (0.01%) and 1 (0.01%), respectively. The presence of the double mutant K103N/Y181C was 0.05% (n " 5). This prevalence was significantly lower than the prevalence of sequences with at least one resistance-associated mutation for other NNRTIs: efavirenz (4.3%; n " 421), nevirapine (4.3%; n " 421), rilpivirine (7.7%; n " 755) or etravirine (11.7%; n " 1143) (P , 0.001) (Figure 1) .
Among the doravirine resistance-associated mutations, the most frequent mutations were V108I (0.6%; n " 62), Y188L (0.2%; n " 18), H221Y (0.2%; n " 18) and Y318F (0.2%; n " 23) (Figure 2) . The other doravirine resistance-associated mutations were very rare: V106A/M (0.1%; n " 8), G190S (0.1%; n " 5), F227C/L/V (0.1%; n " 12), M230I/L (0.04%; n " 4), L234I (0.01%; n " 1), P236L (0.03%; n " 3) and K103N/Y181C (0.05%, n " 5). In comparison, the prevalence of common NNRTI mutations was as follows: K103N/S (2.1%; n " 208), E138A/G/K/Q/R (6.5%; n " 637), Y188C/H/L (0.2%; n " 22) and G190A/E/S (0.5%; n " 51) (Figure 2 ). Between 2010-12 and 2013-16, there was only a significant increase for K103N/S (2.0% versus 3.0%, P " 0.003) and in G190A/E/S (0.3% versus 0.7%, P " 0.003).
Interpretation of resistance to doravirine, NRTIs and other NNRTIs
The presence of at least one doravirine resistance-associated mutation was interpreted as resistance to doravirine; thus, 1.4% (n " 142) of sequences were considered resistant to doravirine in comparison with 8.5% (n " 833) to rilpivirine, 8.1% (n " 788) to etravirine, 8.3% (n " 809) to nevirapine and 3.9% (n " 348) to efavirenz according to the 2017 ANRS algorithm; 0.8%, 0.5%, 0.9% and 0.9% of the sequences were resistant to both doravirine and rilpivirine or etravirine or nevirapine or efavirenz, respectively. The results were slightly different according to the Stanford algorithm: 9.9% (n " 967) for rilpivirine; 10.0% (n " 979) for etravirine; 7.5% (n " 730) for nevirapine and 9.4% (n " 828) for efavirenz; and 1.0%, 1.0%, 0.6% and 0.6% of the sequences were resistant to both doravirine and efavirenz, or nevirapine or etravirine or rilpivirine, respectively.
For NRTIs, 3.5%, 1.6%, 1.0% and 0.2% of sequences were resistant to zidovudine, lamivudine/emtricitabine, abacavir and tenofovir with both resistance algorithms, respectively. Few samples were considered resistant to doravirine and to zidovudine or lamivudine/emtricitabine or abacavir or tenofovir in 0.4%, 0.4%, 0.09% and 0.02% of cases, respectively.
NNRTI resistance according to the subtype
There was no relationship between subtypes and the presence of doravirine resistance-associated mutations (1.6% and 1.3% in B versus non-B subtypes, respectively, P " 0.168). In contrast, Primary doravirine HIV-1 resistance JAC according to both ANRS and Stanford algorithms, the prevalence of resistance was statistically higher for B than non-B subtypes for nevirapine (11.2% versus 5.12%, P , 0.001 and 8.0% versus 6.8%, P " 0.025, respectively) and rilpivirine (9.3% versus 7.7%, P " 0.006 and 10.7% versus 8.9%, P " 0.003, respectively). The resistance to etravirine was also statistically higher for B subtype only with the Stanford algorithm (10.9% versus 9.0%, P " 0.002).
Discussion
To the best of our knowledge, this is the first study showing that the prevalence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients is very low in a large European database, significantly lower than other NNRTI resistance-associated mutations, affecting antiretrovirals potentially recommended as first line regimen. [8] [9] [10] This occurrence was stable over time and not related to any HIV-1 subtype.
The proportion of non-B subtypes was higher in our study (47.0%) compared with the continuous HIV drug resistance surveillance programme (SPREAD) taking place in 27 countries in Europe from 2002 to 2007 (32.7%) or with the last studies in France or in Italy (30.8%). [11] [12] [13] However, this higher prevalence of non-B subtypes is consistent with their continuous increase in Europe or their high prevalence observed recently in Greece. [13] [14] [15] Thus, our study provides a representative view of HIV subtypes circulating in Western Europe and shows that resistance to NNRTIs was higher for B than non-B subtypes, except for doravirine.
In in vitro studies, the resistance mutations associated with doravirine with the highest fold change were V106A, Y188L and M230L. 4 In the DRIVE-FORWARD clinical study, resistance to doravirine emerged in one participant as a multiple mutant (V106I, H221Y and F227C) in the context of non-compliance. 6 In DRIVE-AHEAD, in the doravirine group, the NNRTI mutations were found in 1.6% of patients. 7 In our study, the prevalence of these resistance-associated Soulie et al.
mutations was very low (,0.2%) and the double or triple HIV mutants showing the highest level of in vitro resistance were virtually absent (,0.001%). [3] [4] [5] Overall, our results showed that primary resistance is currently less frequent for doravirine than for other second-generation NNRTIs such as etravirine and rilpivirine. This difference could be explained by some resistance mutations associated with etravirine or rilpivirine, e.g. V90I, A98G, V106I, V179D/F/T and particularly E138A, which are not included in the doravirine resistanceassociated mutations list. For example, E138A was present in 4.2% of the sequences in this study. Similarly, the prevalence of the E138A polymorphic substitution, which can decrease rilpivirine susceptibility, was 3.2% (95% CI 1.9%-4.6%) in 2010-11 in patients with antiretroviral-naive chronic HIV-1 infections in France. 16 One limitation of this study is its descriptive aspect. It would be interesting to study further the impact of these resistance-associated mutations on doravirine phenotypic susceptibility and virological response.
These results are very reassuring in the perspective of the use of doravirine in naive patients as doravirine remains active against the commonly transmitted efavirenz and rilpivirine mutations in vitro. However, the role of doravirine in vivo remains to be confirmed through clinical observations, particularly because patients harbouring NNRTI-resistant virus were deliberately excluded from clinical trials completed so far.
